Shire gets EC approval for hereditary angioedema jab

30th Nov 2018 07:23

(Sharecast News) - Shire's injectable treatment for hereditary angioedema (HAE) has been cleared for launch in European, having enjoyed early success in the US.The European Commission gave Takhzyro, a monoclonal antibody that inhibits formation of the enzyme kallikrein that triggers hereditary angioedema, marketing authorisation in prevention of recurrent attacks of the condition in patients aged 12 years and older.Takhzyro is the first fully human antibody treatment on the market to treat HAE and help prevent attacks of the rare, genetic and potentially life-threatening disorder."We are delighted to receive today's European approval. For those with HAE, the burden of disease can significantly impact their day to day life," said Andreas Busch, Shire's head of research and development. "With Takhzyro, we can now provide an innovative treatment that has potential to change the way HAE is currently treated."In the FTSE 100 company's third-quarter results, it hailed the "encouraging early trajectory" of the treatment since its US launch in mid August, with $51m taken from initial launch stocking.FTSE Russell confirmed overnight that Shire's last day of dealings after its takeover by Takeda Pharmaceuticals will be Friday 4 January.